Bonti will be an innovative leader in both aesthetic and therapeutic markets by turning the science of neurotoxins into beneficial patient and healthcare provider solutions which will improve lives by successfully addressing key unmet market needs.
Our lead product candidate is Bonti EB-001. It is a unique botulinum neurotoxin which has a mechanism of action similar to currently marketed neurotoxin products. And we are targeting a differentiated clinical profile:
- Fast onset of action for EB-001: About 24 hours. Current BoNT/As have an onset of action around 3 – 7 days
- Short duration of effect for EB-001: About 4 weeks. Current BoNT/As have a duration of effect around 3 – 4 months
Key EB-001 benefits include:
- Target Therapeutic Profile: Treats muscle hyperactivity, the root cause of musculoskeletal pain not just symptoms, in both post-surgical and non-surgical settings
- Target Therapeutic Profile: Potential to be a long-acting, non-opioid local muscle relaxant without the side effects of currently marketed products
- Target Aesthetic Profile: Differentiated clinical profile is ideal for addressing currently marketed neurotoxin products’ limitations
Learn how our molecule works and why it will excel in our targeted aesthetic and therapeutic markets.